Nasdaq Biotechnology Ishares ETF (IBB)
$113.31 0.37 (0.33%)
4:00 EDT IBB Stock Quote Delayed 20 Minutes
Previous Close $112.94
Market Cap 9.85B
PE Ratio -
Volume (Avg. Vol.) 200
Day's Range 112.94 - 112.94
52-Week Range 92.15 - 123.92
Dividend & Yield 0.31 (0.28%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
By Ian Cooper
Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.
The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, is up 16.65% since Oct. 1, pushing its year-to-date gain to 26.57% as of Dec. 20. That after months of investors pulling money from actively managed biotech funds, but that situation is starting to correct as well as data out this month indicate investors are warming to biotech assets again.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
Netflix, IBM, Abbott Labs, Domino's Pizza and the IBB ETF were our top stock trades to watch for Thursday, the last trading day this week.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
Regardless of political risks, there are still valuable opportunities in some healthcare stocks. Here are three to consider.
The charts for the IBB ETF in multiple time frames suggest the recent rally in biotech stocks is overdone for the time being.
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
This morning I am recommending a bullish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB). I like the biotech sector, and it has generally been holding up well during the recent volatility.
From Talk Markets
From Market News Video
Investors in iShares Trust - iShares Nasdaq Biotechnology ETF (IBB) saw new options become available this week, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IBB options chain for the new May 22nd contracts and identified one put and one call contract of particular interest.
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation